$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
用比卡鲁胺治疗时要注意什么事项?
2025-10-19 11:44:20
Check Details
比卡鲁胺去哪能买到?
2025-10-19 11:44:20
Check Details
Bicalutamide注意事项
2025-10-19 11:44:20
Check Details
Bicalutamide上市了吗?
2025-10-19 11:44:20
Check Details
达洛鲁胺(Darolutamide)有效延长非转移性,去势抵抗性前列腺癌3年生存率
2025-10-19 11:44:20
Check Details
统计分析证实,在mCRPC中,卡巴他赛优于阿比特龙或恩杂鲁胺
2025-10-19 11:44:20
Check Details
PARP抑制剂对晚期前列腺癌的适应症
2025-10-19 11:44:20
Check Details
联合免疫疗法给晚期前列腺癌患者带来益处
2025-10-19 11:44:20
Check Details
FDA授予EPI-7386治疗mCRPC的快速审核资格
2025-10-19 11:44:20
Check Details
奥拉帕尼显著提高mCRPC亚组的总生存期
2025-10-19 11:44:20
Check Details
新型BiTE免疫肿瘤药物治疗mCRPC的早期疗效观察
2025-10-19 11:44:20
Check Details
奥拉帕尼获批用于治疗转移性去势抵抗性前列腺癌
2025-10-19 11:44:20
Check Details
1
2
...
7546
7547
7548
7549
7550
7551
7552
...
10233
10234
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Post-Enzalutamide mCRPC: HRR/PARP, PSMA Radioligand, and Chemotherapy Sequencing
2
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
3
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
4
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission
5
Bedaquiline for Drug-Resistant TB: 24-Week Regimen, Combination Duration, and When to Stop or Extend
6
Acalabrutinib Dosing and Combination Regimens: CLL/SLL, MCL, Safety Adjustments
7
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
8
Bosutinib for Ph+ CML: Indications, Dosing Adjustments, and Hepatic/Renal Safety
9
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
10
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
11
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
12
AZA+VEN+IVO Triplet Therapy for Newly Diagnosed IDH1 AML: High Response Rates and Durable Efficacy